German health data reveals how rare heart condition affects patients
NCT ID NCT07494656
First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This study uses anonymous health insurance records from Germany to learn more about a rare heart condition called ATTR-CM, where abnormal protein builds up in the heart. Researchers will look at survival rates, hospital visits, and how common the disease is. No new treatments are being tested—this is about understanding the disease better from real-world data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1 person
The number who actually took part.
- Started
-
Apr 2026
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of adults insured under the German statutory health insurance system who were newly identified with transthyretin amyloid cardiomyopathy (ATTR-CM) between 2020 and 2022.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adults aged 18 years or older at the time of the index date Individuals with a newly identified transthyretin amyloid cardiomyopathy (ATTR-CM) diagnosis between January 2020 and December 2022, identified using a validated claims-based algorithm Evidence of amyloidosis, defined as: At least one inpatient diagnosis or At least two outpatient diagnoses in separate quarters Evidence of cardiac involvement, defined as at least one diagnosis of cardiomyopathy or heart failure occurring within a defined temporal window before or after the amyloidosis diagnosis Continuous enrollment in German statutory health insurance for: At least 8 quarters prior to the index date, and At least 4 consecutive quarters after the index date (or until death) Exclusion Criteria: Evidence of light-chain (AL) amyloidosis, including: AL-specific treatment prescriptions Chemotherapy associated with amyloidosis Diagnosis of multiple myeloma autologous stem cell transplantation Diagnosis of amyloid angiopathy Prior amyloidosis diagnosis during the 2-year wash-out period before the index date Missing or implausible information on sex Additional Criteria for Tafamidis Subgroup At least one prescription of tafamidis 61 mg during follow-up No prescriptions for other disease-modifying therapies for transthyretin amyloidosis with polyneuropathy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Attr-CM (transthyretin amyloid cardiomyopathy) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Berlin, 10117, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.